JP2022151432A

JP2022151432A - Agents for treating myocarditis and pericarditis

Info

Publication number: JP2022151432A
Application number: JP2021081956A
Authority: JP
Inventors: 均石井; Hitoshi Ishii
Original assignee: Individual
Current assignee: Individual
Priority date: 2021-03-26
Filing date: 2021-03-26
Publication date: 2022-10-07

Abstract

To provide agents for treating myocarditis and pericarditis.SOLUTION: Provided herein is an agent for treating myocarditis and pericarditis, where the agent is a denaturing agent that destroys DNA and RNA of bacteria, viruses or parasites that have invaded a human body to cause myocarditis and pericarditis, thereby prevents the proliferation of pathogens and treats myocarditis and pericarditis.SELECTED DRAWING: None

Description

本発明は、心筋炎と心膜炎の治療薬に関する。The present invention relates to therapeutic agents for myocarditis and pericarditis.

心筋炎と心膜炎を根本的に治療する薬がない。There is no drug that can cure myocarditis and pericarditis fundamentally.

心筋炎と心膜炎の治療薬を提供することを目的とする。It is intended to provide a therapeutic agent for myocarditis and pericarditis.

本発明の目的を達成するため、次の構成を採用する。
心筋炎とは、主に細菌やウイルスなどが心臓の筋肉である心筋に感染し心筋細胞に炎症が起こる病気。心膜だけに炎症が起こった場合を心膜炎という。
変性剤を人体に投入することにより、心筋炎と心膜炎の原因である身体に侵入した細菌やウイルスなどのＤＮＡとＲＮＡを壊すことにより増殖を防ぎ、心筋炎と心膜炎の治療をする。
細菌やウイルスなど心筋炎と心膜炎の病原体は、核酸を持っている。
核酸とは、ＤＮＡとＲＮＡのことである。
ＤＮＡとＲＮＡは塩基間で水素結合しているが、変性剤を加えてアルカリ性にすると、水素イオンを放出するため変性し、ＤＮＡとＲＮＡの塩基間の水素結合が壊れる。
変性剤を加えてＤＮＡとＲＮＡを壊すことにより、細菌やウイルスの増殖を防ぐことができるため、変性剤という心筋炎と心膜炎の治療薬となる。
心筋炎と心膜炎の部分を標的とする変性剤を有効成分とするリポソーム医薬品として、人体に投与する方法もある。In order to achieve the objects of the present invention, the following configuration is adopted.
Myocarditis is a disease in which the myocardium, which is the muscle of the heart, is mainly infected by bacteria and viruses, and the myocardial cells become inflamed. When only the pericardium is inflamed, it is called pericarditis.
By injecting a denaturing agent into the human body, the DNA and RNA of bacteria, viruses, etc. that have invaded the body that are the cause of myocarditis and pericarditis are destroyed, thereby preventing their proliferation and treating myocarditis and pericarditis. .
Pathogens of myocarditis and pericarditis, such as bacteria and viruses, carry nucleic acids.
Nucleic acids refer to DNA and RNA.
DNA and RNA are hydrogen-bonded between bases, but when a denaturing agent is added to make them alkaline, they release hydrogen ions and denature, breaking the hydrogen bond between bases of DNA and RNA.
By adding a denaturing agent to destroy DNA and RNA, it is possible to prevent the growth of bacteria and viruses.
There is also a method of administering to the human body as a liposome drug containing a modifying agent as an active ingredient that targets myocarditis and pericarditis.

変性剤という心筋炎と心膜炎の治療薬を人体に投与することにより、心筋炎と心膜炎を治療する。代表的な変性剤は、尿素薬がある。Myocarditis and pericarditis are treated by administering therapeutic agents for myocarditis and pericarditis called denaturing agents to the human body. A representative denaturant is a urea drug.

変性剤という心筋炎と心膜炎の治療薬を手術により、心臓に注入する。
心筋炎と心膜炎の部分を標的とする変性剤を有効成分とするリポソーム医薬品として、飲み薬として飲むか、注射により投与する。
代表的な変性剤は、尿素薬がある。A denaturing agent, a drug used to treat myocarditis and pericarditis, is surgically injected into the heart.
As a liposomal drug containing a modifying agent that targets the area of myocarditis and pericarditis as an active ingredient, it is taken orally or administered by injection.
A representative denaturant is a urea drug.

Citation

特願２０２０－１５５８６２Patent application 2020-155862

Claims

As a treatment method for myocarditis and pericarditis, a denaturing agent is administered to the human body to cause degeneration, and the DNA and RNA of bacteria, viruses, and parasites that invade the body that cause myocarditis and pericarditis are destroyed. A myocarditis and pericarditis remedy called a denaturing agent to prevent growth by destroying and treating myocarditis and pericarditis.